$LMNGF News
Last published 4y ago
- 4y agoBVAXFLMNGFBiovaxys Announces Major Research Collaboration With The Ohio State University To Develop Broadly Reactive Pan-Sarbecovirus VaccinePR NewswireVANCOUVER, BC, Dec. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company developing novel approaches to harness T cells to treat cancer and to detect an
- 4y agoBVAXFLMNGFBioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine PlatformPR NewswireVANCOUVER, BC, Nov. 18, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA: 5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company, is pleased to announce that its Chief Medical Officer David Berd, MD, has
- 4y agoBVAXFLMNGFBioVaxys Co-Founder and Chief Medical Officer David Berd, MD, to Present at World Vaccine & Immunotherapy Congress West Coast 2021PR NewswireVANCOUVER, BC, Nov. 17, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA: 5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company, announced today that Company Co-Founder and Chief Medical Officer David Ber
- 5y agoBVAXFLMNGFBioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTHPR NewswireVANCOUVER, BC, Nov. 9, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that results from its in vivo animal research study support the safety and tolerability of CoviDTH at
- 5y agoBVAXFLMNGFBioVaxys Further Expands Intellectual Property Portfolio in Global MarketsPR Newswire- Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA: 5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has br
- 5y agoBVAXFLMNGFBioVaxys Files US Patent Application for Pan-Sarbecovirus VaccinePR NewswireVANCOUVER, BC, Oct. 20, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application
- 5y agoBVAXFLMNGFBioVaxys Announces BVX-0320 Poster Presentation at ISIRV-WHO Virtual ConferencePR NewswireSARS-Cov-2 spike protein vaccine induced strong antibody and T cell responses in murine model VANCOUVER, BC, Oct. 8, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that a pos
- 5y agoBVAXFLMNGFNOTVBioVaxys Begins Toxicity Study Ahead of CoviDTH IND SubmissionPR NewswireVANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has started its planned in vivo animal toxicology study of CoviDTH in parallel with the prepara
- 5y agoBVAXFLMNGFBioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteinsPR Newswire- Potential for superior tolerability to mRNA and Adenovirus Vector vaccines - Production Agreement signed with Millipore-Sigma for SARS-CoV-2 Vaccine Supply VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Te
- 5y agoBVAXFLMNGFBioVaxys Engages Life Sciences Public Relations and Market Communications Firm 6 DegreesPR NewswireVANCOUVER, British Columbia, Sept. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys") announced today that it has engaged life sciences and healthcare communications firm 6 Degrees to handle its strategic
- 5y agoBVAXFLMNGFBioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction MilestonePR NewswireVANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys"), announced today that cancer vaccine manufacturing partner Bio Elpida in Lyon, France, has reached major milestones in
- 5y agoBVAXFLMNGFBioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH ProgramsPR NewswireVANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-
- 5y agoBVAXFLMNGFFDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTHPR NewswireVANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA:5LB) (OTCQB:BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Writte
- 5y agoBVAXFLMNGFBioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical DevelopmentPR NewswireVANCOUVER, British Columbia, June 14, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND request for a
- 5y agoBVAXFLMNGFBioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine StudyPR NewswireVANCOUVER, BC and LYON, France, June 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "the Company") is pleased to announce that its bioproduction partner Bio Elpida of Lyon, France, has initiated const
- 5y agoAWHBVAXFLMNGFBiovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare MarketingPR NewswireVANCOUVER, British Columbia, May 24, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV, FRA: 5LB, OTCQB:BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Charles J. Dunton, MD, has joined BioVaxys as an Advisor to help provide addit
- 5y agoBVAXFLMNGFBioVaxys Announces Appointment of Policy AdvisorPR NewswireVANCOUVER, BC, May 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA:5LB) (OTC:BVAXF) ("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products, today announced th
- 5y agoBVAXFLMNGFBioVaxys Announces Uplisting To The OCTQB Venture MarketPR NewswireVANCOUVER, BC, May 19, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA: 5LB), (OTCQB:BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to announce that it is has been u
- 5y agoBVAXFLMNGFBioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine BioproductionPR NewswireVANCOUVER, BC, May 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (CSE:BIOV) (FRA: 5LB) (OTC:BVAXF) ("BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction agreement ("Agreement") with B
- 5y agoBVAXFLMNGFBioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® DiagnosticPR NewswireVANCOUVER, B.C., April 29, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTC:BVAXF) ("BioVaxys" or "the Company"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it has
- 5y agoLMNGFBVAXFBioVaxys Assigned "BVAXF" By Finra As New US OTC Trading SymbolPR NewswireVANCOUVER, BC and TORONTO, April 21, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA:5LB) (OTC:BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced that effective today it
- 5y agoCSE:BIOVLMNGFBiovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer DayPR NewswireVANCOUVER, BC and TORONTO, April 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancers applications, announced today its sponsorship